Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURSUIT: Adjunctive Lanicemine in MDD
NCT01482221Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2011
- Primary completion
- Aug 2013
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of lanicemine in major depressive disorder (MDD) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline to Week 6 in the Montgomery-Asberg Depression Rating Scale Total Score. Started Dec 2011; status: completed.
02
Drugs
lanicemine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01482221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01482221.